
What happened
Bioengineer César de la Fuente's lab uses ChatGPT and Codex alongside its own deep-learning models to search genomes for antimicrobial candidates, cutting the initial search from years to hours.
Why it matters
The lab turns biology into an information system, reading DNA and peptides as an alphabet to find signals across vast datasets, rather than modifying existing antibiotics—a path de la Fuente says has yielded no new antibiotic class in 50 years.
What to watch
AI only narrows the candidate list; the test is whether lab validation and years of trials turn any molecule into an approved drug. Watch the projected annual death toll, roughly doubling by 2050.
WHO IT HITSThis lands on drug-discovery researchers and cross-disciplinary lab teams who spend years screening molecules, showing how AI tools can compress that early search. It matters most for teams hunting new antibiotics as resistance grows.
Ask the AI about this article →
Summaries like this, in your inbox every morning.
De la Fuente's lab is trying to solve a familiar bottleneck in drug discovery: finding a promising molecule takes years. The lab's answer is to treat biology as an information system. DNA and peptides are, in his words, like an alphabet, and deep-learning models can be trained to read patterns across genome and protein datasets far faster than manual screening. That approach can shrink the earliest search phase from years to hours.
The lab works across biology, chemistry, computer science, and engineering. ChatGPT and Codex help bridge those disciplines: biologists can write code, programmers can work on biological problems, and members can review unfamiliar topics or process large datasets in their native languages. De la Fuente also uses AI as a brainstorming partner, feeding it ideas from many lab members, though he cautions that accuracy must always be double-checked.
A promising candidate, however, is only a starting point. Before any molecule becomes a medicine, it must be confirmed to kill the target microbe, tested for safety and toxicity, assessed for how readily resistance develops, and manufactured reliably, then face regulatory review and clinical trials. The outcome hinges on that slow, grounded work joining the fast AI search—which is exactly why de la Fuente argues AI and laboratory biology must advance together.
For example, today's edition would include:
AI-summarized, only the topics you pick — one digest a day via Email, Slack, or Discord.
Free · 30 seconds with Google · unsubscribe anytimeWhat is AIToday? →
Ask AI anything about this article. Q&As are published on this page for other readers too.
DeepSeek launched V4.1-Flash, a 763B-parameter open-weight model with a causal encoder-decoder architecture

Dynatrace acquired Arize AI, adding AI observability, evaluation and agent monitoring to its application obser…
A Daily Dose of Data Science test kept LoRA adapters separate from a shared 7B base model, cutting 100 fine-tu…

A report by Spencer Kitts, Thomas Larsen and Sydney Von Arx says an OpenAI agent swarm very likely ran an atta…

Simon Willison wrote that many people, himself included, have gone through an existential crisis when a coding…

Stephen Aarons, a New Mexico defense lawyer of over 40 years, was held in direct contempt and fined $5,000 for…
